Merck & Co (MRK) Has Billions in Revenue to Defend. Can its Pipeline Do the Job?

On September 24, Merck & Co., Inc. (NYSE:MRK) announced positive topline results from its pivotal Phase 2b/3 BRUNELLO trial evaluating remigromig, a potentially first-in-class tri-specific Wnt pathway agonist, in adults with diabetic macular edema (DME). At 52 weeks, both the 0.5 mg and 0.8 mg doses met the primary endpoint by demonstrating non-inferiority to the standard-of-care active control, 0.5 mg ranibizumab, for mean change in best-corrected visual acuity.

While remigromig was generally well tolerated, higher rates of proliferative diabetic retinopathy, vitreous hemorrhage, and adverse event-related discontinuations were observed in the treatment arms. Full year-one data will be presented at the American Academy of Ophthalmology Annual Meeting on October 10.

You Might Also Want To Read: Jim Cramer Explains Why Merck (MRK) Is His Fantasy Defense Stock

Bull Case

For bullish investors, remigromig represents a vital pillar in Merck & Co., Inc.’s pipeline diversification strategy as it prepares for KEYTRUDA’s eventual loss of exclusivity. Validating the Wnt pathway offers a novel, non-anti-VEGF mechanism to address retinal vascular diseases, establishing an important new commercial runway alongside recent cardiometabolic launches like WINREVAIR ($588 million in Q2 2026 sales) and LIPFENDRA.

Crucially, Merck’s core operational engine remains robust, generating $16.6 billion in Q2 worldwide sales (up 5%). This substantial cash flow allows MRK to seamlessly absorb large strategic acquisitions, such as its $6.8 billion buyout of Terns ($2.31 per share GAAP impact), while simultaneously supporting heavy late-stage clinical development in ophthalmology and immunology without over-leveraging its balance sheet.

Bear Case

Skeptics highlight that while efficacy non-inferiority was achieved, the safety signal, specifically the imbalances in vitreous hemorrhage and treatment discontinuations, creates near-term regulatory and commercial overhangs until full data are dissected. This risk is amplified by Merck’s narrowing financial flexibility. Following the Terns deal and Cidara transactions, full-year 2026 non-GAAP EPS expectations were revised to $2.66–$2.76 due to $3.62 per share in one-time charges, significantly pressuring near-term profitability.

Furthermore, revenue remains heavily concentrated in oncology, with KEYTRUDA and KEYTRUDA QLEX accounting for $8.4 billion, or over 50%, of Q2 sales. If pipeline assets like remigromig face safety delays or sluggish adoption, MRK’s ability to offset maturing blockbuster growth could come under scrutiny.

Don’t Miss: Bio-Techne (TECH) Shareholders Approve the Merck KGaA Takeover and Reject the Pay Package

Conclusion

The BRUNELLO trial results provide critical proof-of-concept for Merck & Co., Inc.’s novel ophthalmic asset, reinforcing management’s strategy to build a high-margin, post-KEYTRUDA growth engine. While safety imbalances and temporary earnings dilution from recent M&A present near-term headwinds, MRK’s underlying $16.6 billion quarterly revenue scale and expanding pipeline position it well to capture long-term value if regulatory discussions prove favorable.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years 

Follow Insider Monkey on Google News.